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A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy, including increased age, decreased
contrast nephropathy in cardiac angiography. renal function, diabetic nephropathy, hypertension and
Background. Contrast nephropathy (CN) is a common cause congestive heart failure [4]. It is important to note thatof renal dysfunction after cardiac angiography. Recently, N-ace-
these risk factors are highly prevalent among patientstylcysteine (NAC) has been found to reduce the risk of CN
requiring interventional cardiac procedures. [5, 6].after CT imaging with contrast enhancement. The purpose of
the current study was to evaluate the efficacy of NAC for the The precise physiological insult underlying contrast
prevention of CN in the setting of cardiac angiography. nephropathy is unclear and may well involve the inter-
Methods. Eligible patients were those undergoing cardiac play of several pathogenic factors. These may include vaso-angiography with serum creatinine 1.7 mg/dL. Patients were
constrictive forces [7] resulting in medullary ischemia [8],randomized to one of two groups: Group 1, IV hydration and
decreased production of local prostaglandin-mediatedNAC, 1200 mg one hour before angiography, and a second dose
3 hours after; Group 2, IV hydration and placebo. CN was vasodilatation [7], a direct effect on renal tubular cells
defined as an increase of 0.5 mg/dL in serum creatinine. [9], and damage caused by oxygen radicals [10, 11]. Sev-
Results. Seventy-nine patients completed the study. There eral drug interventions based on one or more of thesewere no significant differences between the groups in baseline
mechanisms have been tested in trials for prophylaxischaracteristics, duration of angiography, mean volume of dye
against the development of renal dysfunction. Amonginfused or mean IV hydration. Contrast nephropathy developed
in 24.0% of subjects, 26.3% NAC, and 22.0% placebo (PNS). these are aminophylline [12], calcium-channel blockers
Among subjects with diabetes mellitus, there was no significant [13], theophylline [14], atrial naturetic peptide [15], man-
difference in the rate of CN between the groups (42.1% NAC,
nitol [16], prostaglandins [17] and endothelin antagonists27.8% placebo; P  0.09). The independent predictors of CN
[18]. Unfortunately, studies have generated few resound-risk were diabetes mellitus and preexisting chronic renal insuf-
ficiency. ingly positive results. Therefore, these treatments are
Conclusions. NAC was not effective for the prevention of not widely utilized. At present, only intravenous hydra-
CN after cardiac angiography. tion and avoidance of nephrotoxic drugs are recognized
as methods to decrease the incidence of contrast ne-
phropathy [16].
Contrast nephropathy is generally defined as acute re- Based on the possible role of oxidative damage in
nal failure occurring within 48 hours of exposure to intra- the kidney following contrast administration, Tepel et al
venous radiographic contrast that is not attributable to postulated that the antioxidant N-acetylcysteine (NAC)
other causes [1]. Although generally mild, it can occa- prevents renal dysfunction. They found that the inci-
sionally result in the need for dialysis treatment, extended dence of contrast nephropathy following computed to-
hospital stays and increased morbidity and mortality [2, 3]. mography (CT) in patients with chronic renal insuffi-
There are well known risk factors for the development of ciency was greatly reduced with NAC [19]. A significant
proportion of contrast nephropathy cases in the hospital
setting occurs after cardiac angiography. We performedKey words: computed tomography, nephrotoxicity, acute renal failure,
radiographic contrast media, interventional cardiac procedures. a prospective, placebo controlled, randomized trial to
determine if oral NAC could decrease the incidence ofReceived for publication April 8, 2002
contrast nephropathy in patients with chronic renal in-and in revised form June 25, 2002
Accepted for publication July 15, 2002 sufficiency receiving contrast media during cardiac angi-
ography procedures. 2002 by the International Society of Nephrology
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Table 1. Patient characteristicsMETHODS
Placebo NACStudy subjects
N  4 N  38 P value
Eligible patients were among those referred for car-
Age years 69.89.7 71.412.2 NS
diac angiography at Winthrop-University Hospital, in- Male/female 28/13 24/14 NS
Ethnicity C/AA/H/O 36/2/3/0 32/4/1/1 NScluding both diagnostic and therapeutic procedures, who
Diabetes % 46.3 50 NShad baseline serum creatinine1.7 mg/dL. Patients were
Hypertension % 64.4 57 NS
enrolled between December 2000 and November 2001. CHF % 23.2 26.8 NS
Diuretic use % 46.8 50 NSSubjects were excluded if they were less than 18 years
Mean systolic BP mm Hg 141.919.5 138.515.4 NSold, the renal disease was determined by a nephrologist
Mean diastolic BP mm Hg 75.510.7 73.311.9 NS
to have a reversible component, patient unwilling or un- Mean weight pounds 175.231.7 171.831.6 NS
Mean baseline BUN mg/dL 42.818.8 41.014.9 NSable to provide informed consent, adequate time prior
Mean baseline SCr mg/dL 2.30.5 2.20.4 NSto angiography was not available to perform the study
Abbreviations are: NAC, N-acetylcysteine; C/AA/H/O, Caucasian/Africanprocedures, patient had any evidence of active athero-
American/Hispanic/Other; CHF, chronic heart failure; BP, blood pressure; BUN,
embolic disease, including but not limited to blue toes, blood urea nitrogen; SCr, serum creatinine.
livedo reticularis or eosinophilia, known prior insensi-
tivity to acetylcysteine, severe asthma, breast feeding
women, severe peptic ulcer disease, or respiratory de-
tify those with a prior history of diabetes mellitus (DM),pression. Patients were excluded also if serum creatinine
hypertension, chronic heart failure (CHF) and identifica-measurements varied by more than 15% in the three
tion of medications being taken. Other pertinent datadays prior to angiography. Women of child bearing po-
collected were patient’s weight, probable cause of thetential not using an approved method of contraception
patient’s underlying renal insufficiency, indication forwere not enrolled. The study protocol and informed con-
cardiac catheterization, blood pressure, record of any dyesent were approved by the hospital’s Institutional Re-
exposure over the preceding four weeks, and laboratoryview Board.
data (comprehensive metabolic profile, liver function
tests, complete blood count, urinalysis, and serum creati-Study design
nine for the week prior to catheterization). Following
Randomization was performed using a computer gen-
cardiac catheterization, pertinent data recorded included
erated randomization list by the research pharmacy. Eli-
any side effect(s) due to study drug, blood urea nitrogen
gible patients were randomized on a 1:1 basis to one of
(BUN), and serum creatinine immediately after cathe-
the two following arms: (1) Group 1, N-Acetylcysteine terization, at 48 hours and 144 hours following catheter-
(NAC) plus conventional therapy; (2) Group 2, placebo ization, total volume of contrast administered, total IV
plus conventional therapy. hydration administered, and a record of the type of cath-
Conventional therapy consisted of hydration with 1.0 eterization procedure performed.
mL/kg/h of 0.45% saline for up to 12 hours prior to con-
trast administration and continuing for up to 12 hours after Statistical analysis
contrast administration. The actual rate and duration of Contrast nephropathy was defined as an increase in
IV hydration was at the discretion of the nephrologist or serum creatinine of 0.5 mg/dL at 48 hours after angiogra-
cardiologist, who were permitted to modify the regimen phy. Differences between the groups involving continu-
depending on the clinical status of the patient. Only low ous variables were analyzed using the Student unpaired
osmolality nonionic contrast media was used Omnipa- t tests. For discrete variables analysis was performed
que (iohexol; Amersham Health Inc., Princeton, NY, using Fisher’s Exact Test. Multivariate testing was con-
USA). The dose of NAC used for this study was 1200 mg ducted by logistic regression. All results are presented as
orally, administered one hour prior to and three hours mean  standard deviation. Statistical significance was
following cardiac catheterization (total 2400 mg). considered to be P values of less than 0.05.
Study drug was prepared as a mixture of 6 mL NAC
20% solution with 6 mL of orange juice. The juice was
RESULTSadded to mask the sulfurous odor of NAC, as previ-
ously described [20]. A series of “taste tests” were con- Eighty-one subjects were enrolled, and 79 were included
ducted to ensure blinding. Placebo was simply 12 mL of in the final analysis. Two patients were lost to follow-up
orange juice. because of immediate hospital discharge after cardiac
angiography and failure to have subsequent study blood
Data collection work performed. Patient characteristics are presented in
Demographic information was gathered at baseline, in- Table 1. There were no significant differences between
the groups at baseline in any measured parameter. Thecluding age, gender, ethnicity, a review of systems to iden-
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Table 2. Cardiac angiography data
Placebo NAC P value
Mean duration minutes 48.130.9 44.819.1 NS
Mean dye volume mL 84.742.1 77.435.9 NS
Mean hydration volume mL 1061442 1255713 NS
Fig. 2. Change from pre-angiography to 48 hours post-angiography
levels of serum creatinine in individual patients in the placebo and
NAC groups.
Table 3. Risk factors for contrast acute renal failure
RR P value
Diabetes 3.8 0.007
Age per 10 years 0.9 NS
Hypertension 0.8 NS
CHF 1.1 NS
Fig. 1. Acute renal failure developed in a similar number of patients in Baseline SCr 2.1 mg/dL 2.5 0.03
the N-acetylcysteine (NAC) and placebo groups. In patients with diabetes Volume dye per 10 mL 1.0 NS
mellitus, there was statistically significant difference, but a notable trend Volume hydration per 100 mL 1.0 NS
to greater risk for acute renal failure (ARF) in the NAC group. Systolic blood pressure 140 mm Hg
immediately pre-procedure 1.7 0.04
Diastolic blood pressure 90 mm Hg 1.1 NS
cause of renal insufficiency was attributed to diabetic ne-
phropathy in 42% of patients, hypertensive nephrosclero-
risk of renal failure in patients treated with NAC (pla-sis in 29%, chronic glomerulonephritis 7%, polycystic
cebo 5 of 18, 27.8%; NAC 8 of 19, 42.1%; P  0.09).kidney disease in 2%, and undetermined in 20%. The
Nineteen subjects had an initial serum creatinine greaterindication for coronary angiography was an acute coro-
than 2.5 mg/dL. Acute renal failure developed in 5 of
nary syndrome in 15 of 79 patients (19.0%), chronic
12 (41.7%) of these subjects in the placebo group and 3
stable angina or an abnormal stress test 15 of 79 (19.0%), of 7 (42.8%) in the NAC group (P  NS). A measure-
congestive heart failure 6 of 79 (7.6%), combined factors ment of serum creatinine was made immediately post-
21 of 79 (26.6%), preoperative evaluation 5 of 79 (6.3%), angiography to determine if NAC had any direct effect
other 5 of 79 (6.3%), and not clear 12 of 79 (15.2%). on the assay. In the placebo group the mean serum creati-
There were no significant differences between the groups nine was 2.1 mg/dL pre-procedure and 2.2 mg/dL imme-
on the indication for study. diately afterwards (P  NS). In the NAC group the
The mean duration of cardiac angiography was 46.3 pre-procedure serum creatinine was 2.1 mg/dL and was
24.2 minutes. There were no significant differences be- unchanged afterwards (P  NS between the groups).
tween the groups in mean duration, mean volume of There were no adverse events noted after treatment with
infused dye or mean total intravenous hydration admin- NAC administration.
istered (Table 2). Acute renal failure, defined as an in- By univariate analysis, predictors of the development
crease in serum creatinine of 0.5 mg/dL, occurred in 19 of acute renal failure post-angiography were the pres-
of 79 patients (24.0%). An increase of serum creatinine ence of diabetes mellitus, an elevated baseline serum
1.0 mg/dL was found in 5 of 79 patients (6.3%), and creatinine and elevated immediate pre-procedure sys-
an increase of greater than 2.0 mg/dL in 2 of 79 (2.4%). tolic blood pressure (Table 3). Importantly, neither vol-
Both of these latter patients required temporary hemodi- ume of administered contrast dye nor total volume of
alysis support. intravenous hydration were important risk predictors. In
There was no significant difference between the rate addition, although elevated systolic blood pressure was
of renal failure in the placebo (9 of 41; 22.0%) compared a predictor of risk, a history of hypertension by itself
to the NAC (10 of 38; 26.3%; P  NS) study groups was not. Both diabetes mellitus and elevated serum cre-
(Figs. 1 and 2). Among patients with diabetes mellitus, atinine at baseline remained independent predictors of
acute renal failure risk by multivariate analysis.there was a non-significant trend toward an increased
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DISCUSSION while our study protocol administered the drug at 1200
mg one hour prior to the procedure and then three hoursThe objective of this study was to determine whether
afterwards. It would seem unlikely that this differencethe finding of Tepel et al’s study, that is, NAC prevents
in administration schedule would explain the absence ofcontrast nephropathy in patients undergoing CT imaging
NAC efficacy in our study. Orally administered NAC[19], could be extended to include patients undergoing per-
leads to peak serum levels in approximately one hour,cutaneous coronary angiography. These patients as well
and the elimination half-life is 2.1 hours [21]. It is un-as those undergoing other interventional radiographic
likely, therefore, that administration on the day prior toprocedures are becoming the major source of contrast
exposure would be effective. Our administration sched-mediated nephropathy in hospitalized patients [5, 6], and
ule was more rational from the standpoint of pharmaco-the discovery of a simple and effective means by which
kinetics. However, since it cannot be excluded that ato prevent this complication would be widely adopted.
metabolite of NAC might have antioxidant or other fa-Unfortunately, our present study fails to demonstrate
vorable properties, it is possible that earlier administra-that oral NAC prevents acute renal failure following
tion could have been helpful in Tepel et al’s study.cardiac angiography.
It is possible that the difference in study results oc-As discussed later in this article, both the pathogenesis
curred by chance. Our study may have failed to detectof contrast-induced renal dysfunction and the mecha-
a difference in study groups that was truly present (Typenisms of potential NAC protection are poorly under-
II statistical error) or Tepel et al may have found astood. Therefore, they do not provide a strong founda-
difference in study groups that did not represent a truetion upon which to explain the difference in the outcomes
drug effect (Type I error). The magnitude of effect foundof these two studies. However, discussion of the proce-
by Tepel was dramatic, a reduction of contrast nephropa-dural, demographic, pharmacokinetic, and probable dif-
thy from 22% in the placebo group to 2% in the NACferences between the two studies may prove to be useful
group (greater than 90% risk reduction). Such a largein formulating further studies on the possible protective
treatment effect would make it quite unlikely that chance
effects of NAC.
alone would explain the difference in efficacy found in
The definition of renal failure was the same in both the studies. Another possible explanation for the lack
studies: an increase in serum creatinine of 0.5 mg/dL at of effect for NAC might relate to subtle differences be-
48 hours post-contrast exposure. There were differences tween groups in saline diuresis or in diuretic use. Since
between the studies, however, that might help explain we do not have data on actual urine output post-saline
the discrepant results. First, we studied contrast use not infusion, it is possible that certain predisposed patients
in the setting of CT imaging, but instead in cardiac angi- did not have a satisfactory diuresis. The likelihood of
ography. As a result, our patient population was slightly this is diminished by the fact that on average patients
older (by 4 years) and had a greater proportion of received more than the prescribed saline infusion volume
men (66.7 vs. 56.6%) and diabetics (48.1 vs. 32.5%). The and that there were no significant difference in infusion
baseline serum creatinine was similar in the two studies volume between the placebo and NAC groups. In addi-
(2.3 vs. 2.4 mg/dL). Intravenous hydration, which may tion, while there were no significant differences between
reduce the risk of contrast nephropathy, was used in diuretic use in the two groups, we cannot exclude the
both studies. In the study by Tepel et al it appears that possibility that use of diuretics in certain predisposed
approximately 1500 mL of volume was given [19], while individuals might have affected the results.
in our study the amount was somewhat less at 1180 mL. The pathogenesis of contrast-induced renal dysfunc-
Both studies used nonionic, low osmolality contrast dye, tion is incompletely understood [22]. There is some evi-
but patients in our study received a slightly higher mean dence that either renal vasoconstriction and/or tubular
dose (81.6 vs. 75 mL). In addition, as opposed to the toxic damage may play a role. Contrast infusion causes
intravenous injection of dye in CT imaging, in cardiac a brief and transient increase in renal plasma flow and
angiography injection is directly interarterial. On bal- glomerular filtration rate, followed almost immediately
ance, it would appear that subjects in our study probably by a sustained decrease in both of these parameters
had a somewhat higher net risk for developing contrast [23, 24]. In parallel there is a sustained increase in renal
nephropathy. However, acute renal dysfunction devel- vascular resistance. These hemodynamic changes are
oped in a similar proportion of placebo group subjects caused by release of vasoactive mediators in the kidney.
in both studies (22 vs. 21%), suggesting a counterbalanc- The best evidence to date is for the role of endothelin
ing of risk effects. in driving these processes [25–27]. However, a clinical
Another difference between our study and that of trial of an endothelin receptor antagonist failed to dem-
Tepel et al was in the protocol for NAC administration onstrate a protective effect [18]. Moreover, a correlation
[19]. Tepel et al gave the drug at 600 mg orally twice between renal vasoconstriction and the development of
renal failure has not been found in humans [7].daily, the day before and the day of contrast infusion,
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